期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
Multi-omics Analysis of NUDT19 Across Cancer Types and Its Functional Role in Leukemia
1
作者 LI Xiao-Jin FENG Shuai +1 位作者 YUAN Zhong-Tao YANG Tong-Hua 《生物化学与生物物理进展》 北大核心 2025年第10期2627-2649,共23页
Objective Recent studies have highlighted the critical role of NUDT19 in the initiation,progression,and prognosis of specific cancer types.However,its involvement in pan-cancer analysis has not been fully characterize... Objective Recent studies have highlighted the critical role of NUDT19 in the initiation,progression,and prognosis of specific cancer types.However,its involvement in pan-cancer analysis has not been fully characterized.This study aims to systematically explore the expression patterns,clinical significance,and immune-related functions of NUDT19 in various cancer types through multi-omics analysis,further revealing its potential role in cancer,particularly its functional and therapeutic target value in leukemia.Methods To achieve this goal,various bioinformatics approaches were employed to evaluate the expression patterns,clinical significance,and immune-related functions of NUDT19 in tumors and normal tissues.Additionally,we analyzed the mutation characteristics of NUDT19 and its relationship with epigenetic modifications.Using the single-cell analysis tool SingleCellBase,we explored the distribution of NUDT19 across different cell subpopulations in tumors.To validate these findings,qRT-PCR was used to measure NUDT19 expression levels in specific tumor cell lines,and we established acute myeloid leukemia(AML)cell lines(HL-60 and THP-1)to conduct NUDT19 knockdown and overexpression experiments,assessing its effects on leukemia cell proliferation,apoptosis,and invasion.Results Pan-cancer analysis revealed the dysregulated expression of NUDT19 across multiple cancer types,which was closely associated with poor prognosis,clinical staging,and diagnostic markers.Furthermore,NUDT19 was significantly correlated with tumor biomarkers,immune-related genes,and immune cell infiltration in different cancers.Mutation analysis showed that multiple mutations in NUDT19 were significantly associated with epigenetic changes.Single-cell analysis revealed the heterogeneity of NUDT19 expression in cancer cells,suggesting its potentially diverse functional roles in different cell subpopulations.qRT-PCR experiments confirmed the significant upregulation of NUDT19 in various tumor cell lines.In AML cell lines,NUDT19 knockdown led to reduced cell proliferation and invasion,with increased apoptosis,while NUDT19 overexpression significantly enhanced cell proliferation and invasion while reducing apoptosis.Conclusion This study demonstrates the diverse roles of NUDT19 in various cancer types,with a particularly prominent functional role in leukemia.NUDT19 is not only associated with tumor initiation and progression but may also influence cancer progression through the regulation of immune microenvironment and epigenetic mechanisms.Our research highlights the potential of NUDT19 as a therapeutic target,particularly for targeted therapies in malignancies such as leukemia,with significant clinical application prospects. 展开更多
关键词 NUDT19 pan-cancer immunotherapeutic single-cell analysis
在线阅读 下载PDF
低剂量ATG联合低剂量PTCY预防单倍型相合移植患者移植物抗宿主病的回顾性分析
2
作者 雷金美 刘林 +5 位作者 袁忠涛 李玉 罗乐 李小平 黎诗琦 王三斌 《陆军军医大学学报》 CAS CSCD 北大核心 2024年第4期326-330,共5页
目的 回顾性分析低剂量抗胸腺细胞球蛋白(antithymocyte globulin, ATG)联合低剂量移植后环磷酰胺(post transplantation cyclophosphamide, PTCY)预防单倍型相合移植患者移植物抗宿主病(graft versus host disease, GVHD)的疗效及安全... 目的 回顾性分析低剂量抗胸腺细胞球蛋白(antithymocyte globulin, ATG)联合低剂量移植后环磷酰胺(post transplantation cyclophosphamide, PTCY)预防单倍型相合移植患者移植物抗宿主病(graft versus host disease, GVHD)的疗效及安全性。方法 收集2022年1月至2023年2月在中国人民解放军联勤保障部队第九二○医院血液科行单倍型相合移植的90例患者资料,按照研究对象接受不同的GVHD预防方案分为研究组和对照组,研究组为低剂量ATG联合低剂量PTCY组,总共47例;对照组为标准剂量PTCY组,总共43例。对两组患者的植入情况、GVHD的发生情况、生存情况等指标进行分析。结果 (1)两组患者均成功植入,研究组中性粒细胞植入的中位时间显著短于对照组(11 vs 17 d,P<0.05)、血小板植入的中位时间显著短于对照组(12 vs 20 d,P<0.05)。研究组Ⅱ~Ⅳ度aGVHD发生率显著低于对照组(12.8%vs 34.9%,P<0.05)、Ⅲ~Ⅳ度aGVHD发生率显著低于对照组(6.4%vs 20.9%,P<0.05)、非复发死亡率显著低于对照组(6.4%vs 20.9%,P<0.05)、出血性膀胱炎的发生率显著低于对照组(12.8%vs 34.9%,P<0.05)。(2)截至研究结束,两组轻度cGVHD的发生率、中重度cGVHD的发生率、复发率、EB病毒及巨细胞病毒再激活率、总生存率、无进展生存率差异均无统计学意义。结论 对于单倍型相合移植而言,低剂量ATG联合低剂量PTCY方案具有较低的GVHD发生率、非复发死亡率、出血性膀胱炎发生率及植入较快的优势。 展开更多
关键词 单倍型相合移植 移植物抗宿主病 抗胸腺细胞球蛋白 移植后环磷酰胺 药物联合 低剂量
在线阅读 下载PDF
达沙替尼对靶向CD123的CAR-T治疗AML及不良反应的控制作用1例报告及文献复习
3
作者 李春敏 李玉 +5 位作者 袁忠涛 刘林 罗乐 李小平 王三斌 黎诗琦 《陆军军医大学学报》 CAS CSCD 北大核心 2024年第4期347-351,共5页
目的 初步探索靶向CD123的嵌合抗原受体T细胞(chimeric antigen receptor T cells, CAR-T)治疗复发急性髓系白血病(acute myeloid leukemia, AML)的效果及达沙替尼对靶向CD123的CAR-T治疗AML引起的不良反应的效果。方法 收集第九二○医... 目的 初步探索靶向CD123的嵌合抗原受体T细胞(chimeric antigen receptor T cells, CAR-T)治疗复发急性髓系白血病(acute myeloid leukemia, AML)的效果及达沙替尼对靶向CD123的CAR-T治疗AML引起的不良反应的效果。方法 收集第九二○医院血液科2019年9月收治的1例复发AML患者资料,患者既往多线化疗后复发,入组接受靶向CD123的CAR-T治疗。观察患者治疗后的血象变化,出现粒细胞缺乏时使用达沙替尼(40 mg口服,每8小时1次),粒细胞缺乏缓解即停用达沙替尼。观察患者治疗期间血象变化、CAR-T扩增及疾病控制情况。随访时间超过1年。结果 患者骨髓流式检测微小残留病在CAR-T回输第30天转阴,输注CAR-T细胞后患者无病生存1年。患者回输靶向CD123 CAR-T细胞后观察到CAR-T细胞显著扩增的同时出现粒细胞缺乏及细胞因子释放综合征(cytokine release syndrome, CRS),在使用达沙替尼后CAR-T细胞扩增受抑制并伴随血象恢复,CRS症状缓解,停止使用达沙替尼后CAR-T细胞再次扩增且血象再次下降。结论 靶向CD123的CAR-T细胞对复发AML有一定疗效,初步显示达沙替尼对CAR-T细胞的扩增和功能具有关闭作用,并可缓解靶向CD123的CAR-T治疗引起的骨髓抑制,避免严重CRS发生。 展开更多
关键词 嵌合抗原受体T细胞 急性髓系白血病 CD123抗原 达沙替尼 细胞因子释放综合征
在线阅读 下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部